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Objective: To examine if the protective effect of parasite infection on experimental 
autoimmune encephalomyelitis (EAE) was due to interleukin (IL)-5, a cytokine produced 
by a type-2 response that induces eosinophilia. We hypothesize that, in parasite infec-
tions, IL-5 also promotes expansion of antigen-specific T  regulatory cells that control 
autoimmunity.
Methods: Nippostrongylus brasiliensis larvae were used to infect Lewis rats prior to 
induction of EAE by myelin basic protein. Animals were sham treated, or given blocking 
monoclonal antibodies to interleukin 4 or 5 or to deplete CD25+ T cells. Reactivity of 
CD4+CD25+ T regulatory cells from these animals was examined.
results: Parasite-infected hosts had reduced severity and length of EAE. The beneficial 
effect of parasitic infection was abolished with an anti-IL-5 or an anti-CD25 monoclonal 
antibody (mAb), but not anti-IL-4 mAb. Parasite-infected animals with EAE developed 
antigen-specific CD4+CD25+ T  regulatory cells earlier than EAE controls and these 
expressed more Il5ra than controls. Treatment with IL-5 also reduced the severity of EAE 
and induced Il5ra expressing CD4+CD25+ T regulatory cells.
interpretation: The results of this study suggested that IL-5 produced by the type-2 
inflammatory response to parasite infection promoted induction of autoantigen- 
specific CD25+Il5ra+ T regulatory cells that reduced the severity of autoimmunity. Such a 
mechanism may explain the protective effect of parasite infection in patients with multiple 
sclerosis where eosinophilia is induced by IL-5, produced by the immune response to 
parasites.
Keywords: parasite infection, Treg cells, interleukin-5, autoimmunity, experimental autoimmune 
encephalomyelitis
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inTrODUcTiOn
Correale and Farez observed that multiple sclerosis (MS) does 
not relapse in patients with eosinophilia from parasitic infection 
(1) and that eradication of parasites led to relapse of MS and loss 
of eosinophilia (2). The effect was demonstrated to be due to 
increased CD4+CD25+ T regulatory cells (Treg) (1) and regula-
tory B cells (3). Administration of parasites to modulate MS (4, 5) 
and other autoimmune diseases (6) has been trialed with limited 
effect (7). In these MS studies, the animal-derived parasites do not 
survive in humans so any effect of the parasites on the immune 
system was transient. There are major ethical issues with use of 
parasites that are human pathogens. This has led to attempts to 
identify antigens or chemicals in parasites that impede immunity 
and would not require infection with a pathogenic parasite, 
reviewed in Ref. (7, 8).
Hosts infected with parasitic worms can have reduced immune 
responses to autoantigens administered to induce autoimmu nity, 
reviewed in Ref. (7) as well as vaccines (9) and infections, such 
as tuberculosis (10), malaria (11), HIV (12), and cholera (13). 
Thus, parasites of different species induce an immune inhibi-
tory response to a variety of different antigens and pathogenic 
immune responses.
Parasitic infections induce a type-2 response that is initiated 
by innate lymphoid cells 2 (ILC2)-producing interleukin (IL)-5, 
IL-9, and IL-13 (14, 15), which induces CD4+ T helper 2 (Th2) 
cells that secrete IL-4, IL-5, and IL-13 (15). ILC2 and Th2 cells 
promote parasite expulsion (16). Parasites also induce Treg that 
can prevent immune-mediated elimination of parasites leading to 
chronic parasitic infections (9).
Diversion of T  cell responses to a Th2 phenotype has been 
associated with a tolerogenic and less inflammatory immune res-
ponse, including inhibition of pathogenic Th1 (17, 18) and Th17 
(19) responses. Inflammatory responses to parasitic worms 
produce IL-5, which induces eosinophilia that in some models 
pro motes parasite elimination (20) and in others prevent effective 
immunity (21, 22). The Th2 response to parasites also expands 
CD4+CD25+FOXP3+ Treg (23, 24) and other immune regulatory 
mechanisms, reviewed in Ref. (7, 8).
Experimental autoimmune encephalomyelitis (EAE), the ani-
mal model of MS, can be induced by immunization with autoanti-
gen, which activates Th1 (25) and Th17 (26) effector responses, but 
a Th2 response is also induced and produces IL-4, IL-5, and IL-13 
(25, 27, 28). Spontaneous recovery from EAE is associated with 
activation of Treg that promote recovery (29, 30). Parasitic infec-
tions reduce severity of EAE, including Th17 response and T cell 
infiltration to central nervous system (CNS) (31, 32). Parasitic 
infections that reduce severity of EAE and induce Treg include 
Trypanosoma cruzi (33), Plasmodium chaubaudi (34), Trichinella 
spiralis (35), and Nippostrongylus brasiliensis (36). Recently, 
it was reported IL-5 and IL-33 may mediate the protective effect 
of parasite infection on autoimmunity (36).
Our hypothesis is based on our observations about antigen-
specific CD4+CD25+FOXP3+ Treg that mediate immune toler-
ance, reviewed in Ref. (37–39). These studies led us to recognize 
that antigen-specific Treg depend upon cytokines other than IL-2 
and IL-4 (40–43) and that one such cytokine is IL-5 (43). This 
hypothesis is illustrated in Figure 1. The key finding related to 
this study is naïve CD4+CD25+FOXP3+ Treg activated with an 
autoantigen or alloantigen and rIL-4, not IL-2, are induced to 
express IL-5Rα, the specific receptor for IL-5 (19, 44).
Our hypothesis is supported by a number of findings in allo- 
and autoimmunity. First, we observed that treatment with IL-5 
inhibits allograft rejection (45) and experimental autoimmune 
neuritis (19). Treatment with rIL-5 to suppress autoimmunity 
and allograft rejection depends upon host IL-4 (19, 45) and 
CD25+ T cells (19). The treatment with rIL-5 inhibits Th1 (19, 45) 
and Th17 responses (19). Second, we observed that animals toler-
ant to an allograft have CD4+CD25+FOXP3+ Treg that express 
IL-5Rα and respond to specific alloantigen in the presence of 
rIL-5 (46). Third, we observed that the CD4+ T cells from tolerant 
animals lose the capacity to transfer tolerance in culture unless 
they are activated by specific donor alloantigen and cytokines 
in supernatant from Con A-activated lymphocytes (40, 42). 
Cytokines that maintain these antigen-specific CD4+ tolerance 
transferring cells are IL-5 (43) and IFN-γ (42), whereas IL-2 (40) 
and IL-4 (41) do not.
Taken together, these findings show that naïve CD4+ 
CD25+FOXP3+ Treg activated by a specific antigen can be acti-
vated down separate pathways by different cytokines. This is a 
two-step process. With type-1 responses, IL-2 and later IFN-γ or 
IL-12 activate these cells (44, 47). In type-2 responses, first IL-4 
and later IL-5 activate antigen-activated Treg. The second step is 
blocked by the original activating cytokine, thus IL-2 (40) or IL-4 
(41) do not maintain antigen-specific Treg and may inhibit them. 
These findings suggested IL-5 may promote these antigen-specific 
Treg. Thus, we reasoned that IL-5 produced by the inflamma-
tory response to parasite may also expand autoantigen-specific 
Treg that have been first activated by IL-4 and the immunizing 
autoantigen.
In rats, N. brasiliensis infection induces eosinophilia and 
Th2 cytokines IL-4 and IL-5 between 7 and 14 days, after which 
these parameters return to normal by 28  days due to expul-
sion of the parasites (48). This study examined if the inflam-
matory response activated by infection with N. brasiliensis 
(49) produced IL-5 that tipped the balance to further expand 
antigen-specific activated Treg that had already been activated 
by autoantigen and IL-4, see Figure 1. Lewis rats were infected 
with N. brasiliensis (50) 3  days prior to immunization with 
myelin basic protein (MBP) and complete Freund’s adjuvant 
(CFA) to induce EAE. These parasite-infected hosts were treated 
with a monoclonal antibody (mAb) that inhibits IL-5 at the time 
of peak IL-5 production, which blocked the beneficial effects 
of parasite infections and reduced induction of antigen-specific 
Treg. To demonstrate the key role of IL-5, we examined whether 




Lewis and Dark Agouti (DA) rats were bred and maintained at 
the Animal House Liverpool Hospital. The foundations of these 
FigUre 1 | Proposed concurrent pathways of activation of effector CD4+CD25−FOXP3−T cells and CD4+CD25+FOXP3+ tTreg cells in parasite-infected hosts 
immunized with myelin basic protein (MBP) and complete Freund’s adjuvant to induce experimental autoimmune encephalomyelitis (EAE). Upper section shows 
response to parasites and lower section response to MBP. Effector CD4+ T cells with TCR that recognize the parasite antigens are predominantly activated to a 
type-2 response, with initial production of interleukin (IL)-4, then IL-5. Some Th1 and Th17 cells are activated by the parasites. IL-4 has two effects on tTreg. First,  
it polyclonally activates them like IL-2. Second, tTreg with TCR specific to the immunizing antigen are activated by IL-4 to proliferate and express IL-5Rα. CD4+ 
effector T cells that recognize autoantigen are activated to mainly Th1 and Th17 cells with a smaller T helper 2 (Th2) response. IL-2 also has two effects on tTreg. 
First, it both polyclonally expands them. Second, tTreg with receptor for autoantigen are activated to express receptors for Type-1 cytokines IFN-γ and IL-12 
(pathway not illustrated here). These antigen-specific Th1-activated Treg usually control immune inflammation and lead to clinical recovery of EAE. The pathway  
we propose mediates the effect of parasite infection on EAE is induced by type-2 responses. IL-4 activates tTreg with TCR for autoantigen to expand and express 
IL-5Rα. These antigen-specific Treg suppress specific Th1 and Th17 responses, thus further polarizing the response to Th2 (19). Further stimulation with both 
specific antigen and IL-5, not IL-4, induces them to proliferate and differentiate into highly potent antigen-specific Th2-like Treg that inhibit the autoimmune 
response. Our hypothesis is that type-2 response to the parasite infection produces excess IL-4 and IL-5 that as a bystander effect promotes expansion of 
autoantigen-specific Treg that are dependent on IL-5 for their survival.
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colonies were from the Animal Resources Centre, Canning Vale, 
WA, Australia. 10–12-week-old female rats were used in all 
experiments, and groups included littermates and animals from 
other litters. Experiments were approved by the Animal Ethics 
Committee of the UNSW Australia. Lewis rats were immunized 
with 10 mg of bovine MBP emulsified in CFA, as described (25, 28). 
DA rats were immunized with 20 mg DA rat spinal cord emulsi-
fied in CFA as described (51). Animals were monitored daily 
for weight loss and clinical disease was scored as 1+ limp tail, 
2+ hind leg weakness, 3+ paraplegia, 4+ quadriplegia, 5+ death, 
as described (25, 28). In these studies, our immunization proto-
cols induced clinical EAE in Lewis with disease onset by day 13 
in all 34 rats in control groups (Figure 2A).
Preparation of autoantigens
Myelin basic protein was prepared from guinea pig spinal cord as 
described (25, 28). Spinal cord was prepared from exsanguinated 
DA rats, as described (51). Renal tubular antigen (RTA) was 
prepared from Lewis kidneys, as described (17). CFA used was 
incomplete Freund’s Adjuvant (Sigma-Aldrich, St. Louis, MO, 
USA) and 7  mg/ml of heat killed Mycobacterium tuberculosis 
H37 RA (Difco Laboratories, Detroit, MI, USA).
Parasitic infection with Nippostrongylus 
brasiliensis larvae
Nippostrongylus brasiliensis was maintained in female Hooded 
Wistar rats at the University of Adelaide, SA, Australia with local 
ethics approval. Infective third stage larvae (L3) were prepared 
as described (52). Larvae were shipped to Sydney and washed 
three times in sterile PBS. Using an 18-G needle, 1,600 live L3 
larvae in 100 µl of PBS were injected s.c. into the nape of the neck 
of each Lewis rat 3 days before immunization with MBP in CFA.
mab Therapy
TRFK5, anti–human IL-5 IgG1 mAb was obtained from Dr. W. 
Sewell, Center for Immunology, Darlinghurst, NSW, Australia. 
FigUre 2 | Effect of infection with Nippostrongylus brasiliensis on clinical course of experimental autoimmune encephalomyelitis (EAE) induced by inoculation  
of Lewis rats with myelin basic protein (MBP)/complete Freund’s adjuvant (CFA). (a) Clinical score of EAE at 13 days after immunization of all control Lewis rats 
immunized with MBP/CFA (○) (n = 34). All had developed clinical signs of EAE, with 33 having a score of >2. This was significantly more than in the parasite- 
infected EAE hosts (△) (n = 22) (p < 0.0001) in four of five experiments where parasitic infection had a significant effect on EAE. (B) Parasite-infected EAE  
rats ( ) (n = 6) compared to untreated EAE controls (○) (n = 6), had slower onset of paralysis and the peak of disease was delayed; differences significant at day 12 
(p = 0.01), day 13 (p = 0.001), day 14 (p < 0.005), day 15 (p < 0.01), and day 16 (p = 0.025). Treatment with a IL-5 blocking monoclonal antibody (mAb) starting  
at day 11 in parasite-infected EAE rats ( ) (n = 6) abolished the beneficial effects of parasite infection. The severity of EAE was similar to non-infected controls 
between days 11 and 16. Parasite-infected animals with EAE treated with anti-IL-5 mAb had more severe EAE than untreated parasite-infected EAE rats at day 13 
(p = 0.01), day 14 (p < 0.05), day 15 (p = 0.001), and day 16 (p < 0.01). Results from one of three experiments. (c) In another experiment, anti-IL-5 mAb treatment of 
parasite-infected EAE rats ( ) (n = 4) did not increase severity of EAE compared to parasite-infected EAE rats ( ) (n = 5) until day 16 (p < 0.05), day 17 (p = 0.001), 
day 18 (p < 0.01), day 20 (p < 0.05), day 21 (p = 0.01), and day 22 (p = 0.01). Parasite-infected rats had less severe EAE than non-infected EAE control rats (○) 
(n = 11) at day 12 (p < 0.05), day 13 (p < 0.005), and day 14 (p < 0.01). Anti-IL-5 mAb treatment significantly delayed recovery from EAE compared to controls with 
EAE, at day 16 (p < 0.01), day 17 (p < 0.005), day 22 (p = 0.01), and day 23 (p < 0.01). (D) Eosinophil counts at day 14 were increased in parasite-infected EAE 
hosts ( ) compared to EAE controls ( ) (** p < 0.01). Blocking IL-5 with anti-IL-5 mAb ( ) therapy reduced eosinophilia (p < 0.05) but it was still significantly greater 
than EAE controls (p < 0.0003). EAE rats treated with rIL-5 ( )with 5,000 U daily i.p for 10 days starting on day of onset of clinical disease did not have significantly 
different eosinophil counts to parasite-infected EAE hosts but had significantly increased eosinophil numbers compared to EAE controls. (e) Anti-IL-4 mAb 
(MRCOx81) treatment of parasite-infected EAE rats ( ) (n = 5) did not increase the severity of EAE, with similar disease scores to parasite-infected EAE rats with no 
treatment ( ) (n = 5) and significantly less than in control EAE ( ) (n = 5). Data for days 11, 12, and 13 are shown (**p < 0.01, ***p < 0.001). (F) Depletion of CD25+ 
cells by treatment with an anti-CD25 mAb (NDS61) prior to immunization with MBP/CFA in parasite-infected EAE rats (▧) (n = 6) abolished protection conferred by 
parasite infection in EAE rats ( ) (n = 6), with no significant difference in disease severity scores to non-infected EAE controls ( ) (n = 5). Anti-CD25 mAb-treated 
parasitic-infected EAE rats had more severe disease than parasite-infected EAE rats with no treatment, at day 15 (p = 0.003) and day 16 (p = 0.005).
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Although an anti-human IL-5 mAb, TRFK5 blocks rat IL-5 both 
in vivo and in vitro (19). MRCOx81, an anti–rat IL-4 mAb that 
blocks function of rat IL-4 (17) was a kind gift of Dr. Don Mason 
(MRC Cellular Immunology Unit, Dunn School of Pathology 
Oxford University, Oxford UK). TRFK5 and MRCOx81 were pre-
pared as described (53) and given i.p. 7 mg/kg/dose every 4 days 
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for 2 weeks. CD25+ cells were depleted with an anti-CD25 mAb, 
NDS61 (a kind gift of Dr. M. Dallman, Nuffield Department of 
Surgery, Oxford, United Kingdom) that was given i.p. at 7 mg/kg 
on days 4, 3, 2, and 0 before immunization, as described (54) 
(e-mail communication, Dr. G. Tellides, Department of Surgery, 
Yale University, New Haven, CT, USA) (19).
cytokines
Interleukin-5 was cloned and produced as relevant gene trans-
fected Chinese hamster ovary-S (CHO-s) cell supernatant (55), 
characterized and quantified using bioassays in our laboratory, 
as described (17–19). Treatment with rIL-5 was 5,000 U daily 
i.p for 10 days, a dose that inhibits experimental autoimmune 
neuritis in Lewis rats (19).
lymphocyte Preparation and separation
Cells were prepared from spleens and lymph nodes of Lewis 
or DA rats and immunofluorescence staining performed as 
described (19, 44). Anti-rat mAb used were R7.2 (TCR-αβ), G4.18 
(CD3), MRCOx35 (CD4), MRCOx8 (CD8), MRCOx39 (CD25), 
MRCOx33 (CD45RA) (Pharmingen-BD, San Diego, CA, USA) 
and FITC anti-mouse/rat FOXP3 (eBioscience, San Diego, CA, 
USA). Lymphocyte subset analysis used a FACScan (BD, San Jose, 
CA, USA), or FACS Calibur as described (19, 44).
T  cell subsets were enriched by indirect panning to deplete 
CD8+ T cells and B cells (CD45RA+) as described (19, 44, 56) to 
produce populations that were >98% CD4+, <1% CD8+ and <1% 
B cells. To enrich CD25+ cells, we used PE conjugated MRCOx39 
and anti-PE magnetic beads using the MACS system (Miltenyi, 
Bergisch Gadenbach, Germany) as described (19, 44, 56). 
The CD4+CD25+ T cell populations were 90–96% CD25+.
culture of cD4+cD25+ T cells with 
autoantigen
Rat CD4+CD25+FOXP3+ T  cells are slow to proliferate, and 
responses to a specific antigen are small, but can be increased 
by addition of cytokines, in this case rIL-5 (19, 44, 46, 56). 
Detecting proliferation that is specific requires special condi-
tions that eliminate non-specific background proliferation. 
Cell culture medium used was RPMI 1640 (GIBCO, Grand 
Island, NY, USA) supplemented with 100 ng/ml penicillin, 100 
U/ml streptomycin (Glaxo, Boronia, VIC, Australia), 2  mM 
l-glutamine, 5 × 10−5 M 2-mercaptoethanol (Sigma) and 20% 
Lewis or DA rat serum, as described (19). Rat sera produced low 
background stimulation and allowed cytokine mRNA analysis 
with no background in autologous controls, as described (56). 
Stimulator cells were prepared from irradiated syngeneic thy-
mus cells (Lewis or DA) that had been pre-cultured as described 
(19, 56), with no antigen as a control, or specific autoantigen 
MBP or emulsified rat spinal cord or irrelevant autoantigen 
RTA. rIL-5 at 200 U/ml was added to examine if this cytokine 
enhanced the response to specific autoantigen; either bovine 
MBP for Lewis cells or DA spinal cord antigen for DA cells. 
Cultures were for 4 days at 37°C in 5% CO2.
Results of proliferation experiments were expressed as means 
and SDs of proliferation. For comparison of results from different 
experimental groups, data were normalized by calculation of 
the stimulation index, which was proliferation to a specific-
antigen primed self-stimulator cell divided by proliferation to 
an unprimed self-stimulator cells, as described (56).
rT-Pcr
RNA extraction, cDNA synthesis, and semi-quantitative PCR 
were performed on a Rotorgene PCR machine (Corbett Research, 
Mortlake, NSW, Australia) as described (44, 57). Known primers 
for rat Gapdh, Il2, Ifnγ, Il4, Il5 (58), Ifngr, Il5ra, Foxp3, T-bet, 
Gata3 (44), and Il17ra (59), SYBR Green I and Hot Master Taq 
polymerase (Eppendorf AG, Hamburg, Germany) or SensiMix 
DNA kit (Bioline, Alexandria, NSW, Australia) were used as 
described. Gene copy number was derived from a standard curve 
run in parallel and normalized against Gapdh as described (44).
statistics
The clinical score on each day post-immunization were compared 
using a non-parametric Mann–Whitney U test and p <  0.05 
was considered a significant difference. Area under the curve of 
clinical EAE were calculated according to the formula described 
by Fleming et al. (60) and expressed as mean ± SE. Other data 
were expressed as mean and SD and analyzed with an unpaired 
Student’s t-test.
resUlTs
effect of infection with N. brasiliensis  
on clinical course of eae and the  
effects of Blocking il-5
In our laboratory, induction of EAE by MBP/CFA is very reli-
able, with all 34 controls related to experiments described in this 
manuscript, developing clinical disease by day 13 (Figure 2A). 
This allowed confidence that the reduced and delayed course of 
EAE in parasite-infected hosts was an effect of the parasites.
Nippostrongylus brasiliensis infection 3 days before inocula-
tion with MBP emulsified in CFA delayed and reduced the 
severity of EAE in Lewis rats in four of five experiments. The 
one of five experiments where parasites had no effect is not 
included. With the other four experiments, at day 13, there was 
a significant reduced severity of EAE (p < 0.0001) compared to 
controls (Figure  2A). Parasite infection induced eosinophilia 
(Figure 2D).
Given the variability of the rate and tempo of the effects of 
parasite infection on EAE, results of individual experiments are 
shown. In all four experiments where parasites reduced severity 
of EAE, treatment with an anti-IL-5 mAb commencing at 10 days 
after immunization significantly reduced the beneficial effect of 
parasitic infection.
In three experiments, anti-IL-5 mAb treatment reversed the 
delay in onset of EAE seen with parasite infection, and the sever-
ity of EAE was similar to or more severe than non-infected con-
trols. One of these experiments (illustrated in Figure 2B) shows 
parasite infection delayed the day of onset of clinical disease, from 
11 (11–12) days [median (range)] in EAE controls to 14 (11–16) 
days in parasite-infected animals (p = 0.034). 
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In anti-IL-5 mAb-treated parasite-infected animals, the day 
of onset of clinical disease was similar to that of EAE controls, 
12 (11–14) days. The area under the curve for clinical disease 
was less in parasite-infected animals (11.7 ±  1.6) compared to 
EAE controls (20.7 ± 2.4, p = 0.017) and anti-IL5 mAb-treated 
parasite-infected animals (18.0 ± 1.4; p = 0.026).
In one experiment, the effect of anti-IL-5 mAb treatment was 
delayed and the early course of EAE in these animals was similar 
to the untreated parasite-infected EAE group (Figure  2C). 
In this experiment, animals treated with anti-IL-5 mAb had 
a greater peak of disease and recovery was delayed compared 
to untreated EAE-parasite-infected rats and EAE controls 
(Figure 2C). The area under the curve of parasite-infected hosts 
(13.6 ± 2.8) was less than EAE controls (24.5 ± 3.1) (p < 0.05). 
Anti-IL-5 mAb-treated parasite-infected animals area under 
the curve was not different to EAE controls (17.0 ± 2.0). This 
delay in recovery seen in this experiment is consistent with anti-
IL-5 mAb reducing the regulatory mechanisms that inhibit the 
immune response that allow recovery from EAE.
Nippostrongylus brasiliensis infection takes about 7  days to 
induce eosinophilia, so IL-5 appeared well after the activation of 
T cells to MBP. Furthermore, the parasites are expelled by 14 days 
after which IL-5 production rapidly drops.
Treatment with an IL-4 blocking mAb (MRCOx81), com-
mencing at day 10 after immunization had no effect on the 
protective effect of parasitic infection (Figure 2E). This treatment 
served as a control for the anti-IL-5 mAb treatment. The lack of 
effect of anti-IL-4 mAb on the effect of parasites on EAE may 
be due to IL-4 produced by the early Type-2 response activating 
antigen-specific Treg to express IL-5Rα and become dependent 
on IL-5 not IL-4.
Treatment with NDS61 mAb to deplete CD25+ cells before 
immunization with MBP/CFA reduced the protective effect of 
parasitic infection on EAE (Figure  2F). This therapy reduced 
the number of CD4+FOXP3+ T cells in blood when compared to 
untreated controls (1.2–1.6% vs. 2.3–3.8%) at day 28. This showed 
CD25+ cells were required for the beneficial effects of parasitic 
infection.
comparison of cD4+cD25+ T cells  
from Parasite-infected and control  
rats with eae
Spleen cells from parasite-infected and control EAE rats were 
analyzed at 16 days at the peak of clinical disease just before com-
mencement of recovery. The percentage of CD4+CD25+ T cells in 
parasite-infected EAE rats had not increased above the normal 
range of 2–4% (Figure 3A, panels on left).
CD25+ T  cells from control EAE rats and parasite-infected 
EAE rats treated with or without anti-IL-5 mAb were selected by a 
single step enrichment protocol without prior depletion of B cells 
and CD8+ cells. This cell population was 82–87% CD4+CD25+ 
(Figure  3A panels on right) with over 80% FOXP3+ (data not 
shown). Enriched CD25+ T cells were cultured for 4 days with 
irradiated Lewis stimulator cells that have been non-primed 
(self), MBP-primed, or primed with an irrelevant autoantigen 
RTA (Figures  3B,C). Cultures supplemented with rIL-5 were 
compared to those with no cytokine added. CD25+ T cells from 
parasite-infected EAE rats responded to MBP-primed but not 
to non-primed (p < 0.001) or RTA-primed (p < 0.01) stimula-
tor cells. With addition of IL-5 to these cultures, there was a 
small enhancement of the response to MBP-primed stimulator 
(p < 0.05) but not to unprimed or RTA-primed stimulator cells. 
CD25+ T cells from EAE controls rats responded in a non-anti-
gen-specific manner, although the response to MBP was greater 
than RTA (p < 0.05). IL-5 did not enhance the response to MBP 
(Figure 3B). The reason for this higher non-specific background 
response of CD4+CD25+ T  cells from EAE controls was not 
examined, but may relate to the EAE control rats being at the 
peak of clinical disease, with no inhibitory effect from parasites.
As each test cell population has different levels of non-specific 
proliferation, the stimulation index was used for comparison 
between the three groups (Figure  3C). A stimulation index of 
1 or less is no specific proliferation to that antigen. There was 
a marked autoantigen-specific (MBP) response of CD4+CD25+ 
T  cells from parasite-infected animals that was significantly 
greater than that of CD4+CD25+ T  cells from either parasite-
infected EAE rats treated with anti-IL-5 mAb (p = 0.04) or EAE 
controls (p = 0.006). CD4+CD25+ T cells from both EAE controls 
and from anti-IL-5 mAb-treated animals had a modest response 
to MBP-primed stimulator cells. CD4+CD25+ T  cells from all 
groups had no specific response to third-party RTA-primed 
stimulator cells with stimulation indices of around one.
In cultures with rIL-5 added, the response of CD4+CD25+ 
T cells from parasite-infected hosts was greater than that of cells 
from parasite and anti-IL-5 mAb-treated hosts (p =  0.03) but 
not to that of cells from EAE controls. rIL-5 had no effect on the 
lack of response to third-party RTA.
These results showed that at day 16, the CD4+CD25+ T cells 
from parasite-infected hosts had a significant specific response 
to MBP, which was not much greater than that with cells from 
EAE controls or in parasite-infected controls treated with anti-
IL-5 mAb. This was consistent with the parasite infection via 
induction of IL-5 production, accelerating induction of antigen-
specific CD4+CD25+ T cells.
At day 20, when animals had recovered from EAE, both 
parasite-infected groups whether treated with anti-IL-5 mAb or 
not, had a specific response to MBP that was significantly greater 
than to RTA and unprimed stimulator cells (Figure 3D). Taken 
together, these results suggest parasitic infection brings forward 
the development of antigen-specific Treg.
CD25+ Treg from parasite-infected animals expressed more 
Il5ra than those from control EAE rats (Figure 3E). Foxp3 expres-
sion by CD4+CD25+ T cells was greatest in the parasite-infected 
group, and less in the anti-IL-5 mAb-treated parasite-infected 
and control EAE groups. This was consistent with the expan-
sion of the IL-4-induced antigen-specific CD4+CD25+ Treg that 
express Il5ra (19, 44).
effect of Treatment with ril-5 on  
clinical course of eae
Given that blocking IL-5 eliminated the effects of parasitic infec-
tion on EAE, we examined if treatment with rIL-5 alone modified 
FigUre 3 | Comparison of CD4+CD25+ T cells from parasite-infected Lewis rats with experimental autoimmune encephalomyelitis (EAE), with and without anti-IL-5 
monoclonal antibody (mAb) treatment. (a) FACS analysis of splenic T cells at 16 days post-immunization from EAE control rats and parasite-infected EAE rats 
treated with or without anti-IL-5 antibody (panels on left). The proportions of CD4+CD25+ T cells were not different to those from control EAE rats (2.6–3.8% vs. 
2.5–3.9%). The CD4+CD25+ T cells were enriched in single step process to 82–87% of cells (right panel). These enriched samples were tested for proliferation in 
response to autoantigen (B) and expression of specific mRNA by RT-PCR (e). (B) Proliferation of enriched CD4+CD25+ T cells [as described in (a)] in cultures  
with Lewis stimulator cells either unprimed (self) or primed with either myelin basic protein (MBP) or an irrelevant autoantigen renal tubular antigen (RTA). Cells were 
cultured in the presence ( ) or absence ( ) of rIL-5. Proliferation measured at 4 days by 3H-thymidine incorporation. *p < 0.05, **p < 0.01, *** p < 0.001. Cells from 
parasite-infected EAE rats had significantly higher proliferation to specific autoantigen, than to RTA or unprimed stimulators. There was much less proliferation of 
cells from anti-IL-5 mAb treated parasite-infected EAE rats. EAE controls had non-antigen-specific proliferation. (c) Data from 3B, expressed as stimulation indices. 
Response to specific-autoantigen MBP (▧) compared to that to third-party RTA ( ). Upper panel shows stimulation indices of cultures without rIL-5 added 
CD4+CD25+ T cells from parasite-infected rats have higher stimulation indices than those from anti-IL-5 mAb treated parasite-infected hosts (p = 0.04) and EAE 
controls (p = 0.004). A stimulation index of 1 or less shows there is no antigen-specific effect. Thus, all populations did not respond to a third-party antigen, RTA. 
Lower panel shows stimulation indices in cultures with rIL-5 was added. The response to MBP-primed stimulator cells of CD4+CD25+ T cells from parasite-infected 
hosts was greater than that of cells from anti-IL-5 mAb-treated parasite-infected hosts (p = 0.03). There was no specific response to RTA by any cell population. 
Together, these results show that parasite-infected hosts develop more CD4+CD25+ T cells that respond to MBP, and this is abolished by anti-IL-5 mAb treatment. 
This suggests that IL-5 produced in response to the parasite infection enhances the generation of antigen-specific T regulatory cells. (D) Proliferation of enriched 
CD4+CD25+ T cells prepared as described in Figure 3A, from splenic cells taken at day 20 and cultured for 4 days with stimulator cells as described in (B) in the 
presence ( ) or absence ( ) of rIL-5 (**p < 0.01, ***p < 0.001). Proliferation of cells from parasite-infected EAE rats and anti-IL-5 mAb-treated parasite-infected  
EAE was specific for MBP and similar, as all animals had recovered from EAE and had developed autoantigen-specific Treg. There was no response to third-party 
RTA-primed cells. (e) RT-PCR of mRNA from CD25+ T cells prepared as described in (a) from spleens collected at day 23. Expression of Foxp3 and Il5ra relative  
to gapdh in EAE controls, parasite-infected EAE, or anti-IL-5 mAb-treated parasite-infected EAE rats.
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the course of EAE (Figure 4A). Lewis rats with EAE were either 
treated with rIL-5 or supernatant from non-transfected CHO-s 
cell culture commencing at day 11, just before onset of clinical 
EAE. A dose of 5,000 U of rIL-5 per day was given for 10 days as 
this dose markedly reduced nerve demyelination in experimen-
tal autoimmune neuritis (19). rIL-5 therapy reduced the severity 
of EAE within 2 days. EAE was less severe with rIL-5 treatment at 
day 13 (p < 0.005), day 14 (p < 0.05), day 15 (p < 0.005), and day 
FigUre 4 | Effect of therapy with rIL-5 on clinical experimental autoimmune encephalomyelitis (EAE) and induction of interleukin (IL)-5Ra expressing Treg.  
(a) Clinical course of EAE in Lewis rats treated with 5,000 U of rIL-5, daily from onset of clinical disease ( ) (n = 25), compared to EAE in sham-treated controls  
(○) (n = 18). From 2 days after rIL-5 treatment commenced, rats had less severe disease than in controls: day 13 (p < 0.005), day 14 (p = 0.05), day 15 (p < 0.005), 
and day 16 (p < 0.005). Both groups had recovered by 17 days. (B) Clinical course of EAE in Dark Agouti DA rats immunized with autologous spinal cord in CFA 
and treated with 5,000 U of rIL-5, daily from day 8 at onset of clinical disease ( ) (n = 5) compared to EAE in sham-treated controls (○) (n = 5) and those treated 
with a combination of rIL-5 and anti-IL-5 mAb from day 8 ( ) (n = 5). rIL-5-treated animals compared to sham-treated controls had a significantly milder disease at 
day 10 (p < 0.05), day 11 (p < 0.05), day 12 (p = 0.001), and day 13 (p < 0.01). All EAE controls had severe disease and either died or were euthanized at day 13. 
Anti-IL-5 mAb abolished the benefits of rIL-5 treatment at 10–12 days. (c) FACS analysis of enriched CD4+CD25hi and CD4+CD25−/lo splenic T cells from DA rats 
with EAE, with or without IL-5 treatment. Spleen and lymph nodes cells were recovered at 14 days and then cultured for 4 days with spinal cord antigen in the 
presence or absence of rIL-5 before they were enriched for CD4+CD25hi and CD4+CD25−/lo populations. (D) RT-PCR for il5ra and foxp3 expression on CD4+ T cells 
isolated from DA rats and cultured as described in Figure 4C. Results expressed as copies of relevant gene per TCR-α copy number for that specimen to normalize 
for T cell number. CD4+ and CD4+CD25+ T cells from rIL-5 treated hosts had greater il5ra and foxp3 expression than those from control EAE not treated with IL-5. 
Populations depleted of CD4+CD25hi T cells had minimal il5ra and foxp3, even if cultured with rIL-5.
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16 (p < 0.005). By day 17, both groups had recovered (Figure 4A). 
These are combined results from four separate experiments. The 
area under the curve was less in rIL-5 treated (8.9 ± 0.9) (n = 22) 
than in control EAE (15.7 ± 1.9) (n = 18) (p = 0.002).
To examine if the IL-5 effect was present in strains other 
than Lewis rats, a second model of EAE was used. DA rats were 
immunized with autologous spinal cord in CFA was used. rIL-5 
treatment was given from day 8 post-immunization, a few days 
before the onset of clinical disease and continued daily for 10 days 
(Figure 4B). The severity of EAE was reduced in rIL-5 treated rats 
compared to sham-treated controls at days 10 and 11 (p < 0.5), day 
12 (p < 0.005) and day 13 (p < 0.01). Sham-treated EAE controls 
had severe disease and were euthanized at day 13, as required 
by our animal ethics approval (Figure 4B). Animals treated with 
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both rIL-5 and anti-IL-5 mAb from day 8 post-immunization had 
lower clinical paralysis scores than controls at days 10, 11, and 12 
and later recovered. The area under the curve was less for IL-5 
treated (10.8 ± 2.1) than for EAE untreated controls (22.2 ± 0.6) 
(p =  0.008). This was one of four experiments that showed a 
similar effect of rIL-5 therapy on EAE in DA rats.
CD4+ T cells from the spleens of rIL-5-treated and sham-treated 
DA rats were compared by RT-PCR either as freshly isolated or 
after 4-day culture with DA rat spinal cord autoantigen. Cultures 
were either supplemented with IL-5 or had no supplement with a 
cytokine. The cultured CD4+ T cell population was separated into 
CD4+CD25hi T cells (>95% enriched) and CD4+CD25lo T cells 
and subjected to FACS (Figure 4C) and RT-PCR to determine 
gene expression profiles.
Freshly isolated CD4+ T cells from IL-5 treated EAE animals 
had more Foxp3, Il5ra, Il4, Il5, and Gata3 than sham-treated EAE 
controls (data not shown). There was no significant difference in 
expression of Th1-associated genes Il2, Ifng, and Tbet, nor the 
Th17 gene Il17 (data not shown).
After culture with rIL-5, both the unseparated CD4+ T cells 
and CD4+CD25hi T cells from rIL-5-treated EAE rats expressed 
more Foxp3 and Il5ra mRNA than cells from sham-treated EAE 
controls (Figures 4C,D). By contrast, the CD4+CD25−/lo T cells 
had very low expression of Foxp3 and Il5ra (Figure 4D).
Thus, rIL-5 therapy alone reduced severity of clinical EAE, 
accelerated recovery and increased the proportions of Il5ra and 
Foxp3 expressing CD4+CD25+ Treg. This confirmed that the 
effects of parasite infection could have been mediated by IL-5 
alone.
DiscUssiOn
The beneficial effects of environmental acquired parasitic infec-
tions on MS and other autoimmune diseases have been associ-
ated with eosinophilia. Induction of eosinophilia is due to Type-2 
cytokines IL-4 and IL-5 produced by Th2 and ILC2 cells (14, 15) 
in response to the parasitic infection. These clinical observations 
led to studies where patients with MS or inflammatory bowel 
disease are infected with parasites (6, 61–65). Deliberate infec-
tion of patients with a parasite has significant ethical issues, as 
parasites that infect humans can induce morbidity and mortality. 
In clinical studies to date, non-human parasites were given to 
patients, but these are rapidly eliminated and do not produce 
a prolonged Type-2 response and eosinophilia (6, 61–65). This 
may explain why they failed to show a therapeutic benefit. As a 
consequence, there are many investigations of molecules pro-
duced by parasites that alone may induce the Type-2 response 
and eosinophilia, reviewed in Ref. (7, 8). Administration of 
enriched parasitic molecules that induce Type-2 responses and 
eosinophilia may be therapeutic without the risks associated 
from persistent parasitic infection.
As tissue invasive parasitic infection induces type-2 responses 
that produce IL-4, IL-5, and IL-13 (66, 67), and IL-5 induces 
eosinophilia (21), these observations led us to the hypothesis 
examined in this study. We previously observed that IL-5 pro-
motes induction of antigen-specific CD4+CD25+ Treg that 
prevent autoimmune-mediated demyelination in experimental 
autoimmune neuritis (19). We also demonstrated that naïve 
CD4+CD25+FOXP3+ Treg activated by a specific antigen and 
the Type-2 cytokine IL-4, but not the usual Treg cytokine 
IL-2, are induced to express IL-5Rα (44) and that IL-5 further 
activates these antigen-specific Treg (44). Antigen-specific Treg 
that express Il5ra are further expanded by IL-5 and stimulation 
with specific antigen both in vitro (46, 56) and in vivo (19). We 
proposed that tTreg activated by a specific antigen and IL-4 
require IL-5 to promote their survival (43) and their inhibition 
of auto- and allo-immunity (19, 43, 44), as illustrated in Figure 1.
In this study, we examined if the effects of parasitic infec-
tion could be due to increased IL-5, which not only induce 
eosinophilia but also as a bystander effect further expands 
antigen-specific CD4+CD25+ Treg activated by autoantigen 
and IL-4. The observations that supported our hypothesis were 
as follows: (i) infection with the parasitic nematode N. brasil-
iensis reduced the severity of EAE and induced eosinophilia, 
(ii) treatment with an anti-IL-5 mAb blocked this protective 
effect of parasitic infection and partially reduced the level of 
eosinophilia; (iii) compared to EAE controls and anti-IL5 
mAb-treated parasite-infected EAE hosts, parasite-infected 
hosts with EAE had increased numbers of CD4+CD25+ T cells 
that responded to the specific-autoantigen MBP, but not to a 
third-party autoantigen; (iv) depletion of CD25+ cells prior to 
induction of EAE prevented parasitic infection reducing the 
severity of EAE. Treatment with an anti-CD25 mAb that depletes 
CD25+ cells is a standard method of showing CD4+CD25+ Treg 
are required to mediate the effect.
To test Koch’s postulate, we showed treatment with IL-5 
reduced the severity of EAE to a degree comparable to parasite 
infection. We also showed IL-5 treatment, as with parasitic infec-
tion, increased the number of CD4+CD25+ Treg that expressed 
Il5ra.
These findings show parasitic infection mediates part of its 
effect of reducing the severity of EAE via Th2 and/or ILC2 cells 
(14, 15) activated to produce high levels of IL-5. IL-4 produced 
early in the response to parasitic infection may have contributed 
to the initial activation of antigen-activated Treg to induce 
expression of il5ra and subsequent dependence on IL-5.
When first described, Th2 cells were considered anti-inflam-
matory and tolerance-promoting (67). Nasal therapy with MBP 
peptides combined with IL-4 reduces severity of EAE in Lewis 
rats (68). Combining rIL-4 and anti-CD3 mAb therapy reduces 
severity of EAE and inhibits Type-1 responses, but spares type-2 
(25). rIL-4 therapy prevents autoimmune nephritis (17). IL-10 
therapy inhibits EAE, but its effect is abrogated by IL-4 (69). 
In IL-5 knock out mice, the severity and time of onset of EAE 
was similar to wild-type controls, but type-2 responses were 
reduced (70). The effects of parasite infection on EAE in IL-5 
knock out animals are not known. On the other hand, ERK1 
knockout animals have enhanced Th1 responses and reduced 
IL-5 production, and develop more severe EAE (71) consistent 
with type-2 responses modifying EAE. These studies do not 
prove type-2 cytokines directly inhibit autoimmunity, however.
Recently, Finlay et  al. described that immunization with 
Fasciola hepatica secretory/excretory products inhibited EAE and 
reduced Th1 and Th17 responses (36). This effect is associated 
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with type-2 responses, but is not dependent on IL-4, IL-10, or 
Treg. They identified that IL-33 with IL-5, produced by ILC2, 
mediates the effect by induction of eosinophilia (36). In this 
study, blocking IL-5 also reduced parasite-induced protection 
against EAE (36). IL-33 has been shown to reduce EAE by 
inhibition of Th1/Th17 response, as well as enhanced Type-2 
responses and M2 macrophages (72). IL-33 enhances both Th2 
effector responses and activation of Treg by Type-2 cytokines 
(73, 74), thus these findings may complement those described 
here. Other immune regulatory mechanisms may be induced 
by type-2 responses, including alternate activated macrophages 
(M2), which are induced when parasite infection reduces severity 
of EAE (32).
Although the induction of EAE is by Th1 and Th17 responses, 
there is induction of a Th2 response (25, 27). The recovery from 
EAE is driven by induction of antigen-specific CD4+CD25+ Treg 
and is dependent upon IFN-γ (75). This is the Th1 cytokine-
induced pathway for activation of antigen-specific Treg (44, 47) 
that is the major contributor to the spontaneous recovery from 
EAE in controls (75).
The detection of the slow and small proliferation of antigen- 
specific Treg requires culture techniques that eliminate non-
specific background proliferation, as we have previously 
described (19, 44, 46, 56). In this study, CD4+CD25+FOXP3+ 
Treg proliferation to the specific antigen MBP was greater before 
recovery from EAE (day 16) in parasite-infected hosts, than 
EAE controls and anti-IL-5 mAb-treated parasite-infected EAE 
hosts. This response was only to specific-antigen MBP and not 
to RTA or unprimed self-stimulator cells, confirming this was 
an antigen-specific Treg response. This confirmed that parasite-
infected hosts had more MBP-specific CD4+CD25+ Treg than 
EAE controls and anti-IL-5 mAb-treated EAE animals. Further 
CD4+CD25+ T  cells from parasite-infected and IL-5 treated 
hosts expressed more Il5ra than CD4+CD25+ T  cells from 
EAE controls or anti-IL-5 mAb-treated parasite-infected EAE 
animals.
Our interpretation of the effects of parasitic infection is that 
production of IL-4 and IL-5 by the activated Th2 cells and ILC2 
accelerates the induction of autoantigen-specific Treg that express 
Il5ra, which in turn, reduced the severity of EAE. The source of 
the IL-5 in our hosts was not identified but could be Th2 or ILC2 
cells that have been activated in response to parasitic infection 
(36). Late treatment with an anti-IL-4 mAb did not prevent the 
effects of parasites on EAE. We think that by the time anti-IL-4 
mAb was given, the host ILC2 and Th2 cells had already produced 
sufficient IL-4 to activate naïve CD4+CD25+FOXP3+ Treg with 
TCR specific for MBP to express Il5ra. In an allograft tolerance 
model, we showed IL-4 does not sustain the alloantigen-specific 
Treg that mediate tolerance (41), but IL-5 does (43). In other 
models, early blocking of IL-4 prevents induction of il5ra 
expressing Treg and rIL-5 therapy is ineffective (19, 45). With 
parasitic infection and rIL-5 therapy, these autoantigen and IL-4 
activated Treg were further expanded, respectively, by parasite 
infection-induced host type-2 response producing IL-5 or by 
administered IL-5.
Whether or not the benefits of chronic parasitic infection 
where numbers of CD4+CD25+ T cells are increased in patients 
with MS (1, 2) is mediated in part or mainly by IL-5 requires 
investigation.
Historically, IL-5 has been considered pro-inflammatory 
in allergic diseases including asthma. IL-5Rα is not expressed 
by T  cells other than IL-4 and antigen-activated CD4+CD25+ 
FOXP3+ Treg (19, 44). IL-5Rα is mainly expressed on eosinophils, 
mast cells, and basophils, as well as a subpopulation of naïve 
B  cells. Thus, IL-5 cannot activate T effector cells. Trials with 
an anti-IL-5 mAb in asthma showed blocking IL-5 had limited 
or no effect, except in patients with high eosinophil counts, 
reviewed in Ref. (76). Many patients, including those with 
parasitic infection have continued production of IL-5, which 
does not enhance autoimmunity or allergic diseases. The safety 
issues for IL-5 or IL-5 analogs in therapy will require careful 
examination, but may be acceptable. For treatment of chronic 
diseases such as MS, continued treatment may be required as the 
antigen-specific Treg require exposure to IL-5 to maintain their 
function.
The hygiene hypothesis related to autoimmunity and allergy 
can in part be explained by lack of parasitic infections that can 
reduce unwanted immunity, including allergies and autoim-
munity (77). This study suggests IL-5 produced in response to 
parasite infection may mediate a major part of the protection 
from autoimmunity and allergy by activation of antigen-specific 
Treg that have been activated by IL-4.
High levels of IL-5 and the resultant eosinophilia are protec-
tive against some parasite species, but not against others and 
may even be counterproductive (21, 22). The immune response 
that eliminates parasites is complex and varies depending on 
the species of parasites, as well as the type-2 response and 
eosinophilia (78).
Our hypothesis is illustrated in Figure 1. Parasitic infection 
initially activates ILC2 cells producing IL-4, IL-5, and IL-13 
(14, 15), which direct effector cells to differentiate into Th2 
cells. Th2 cells initially produce IL-4 and later produce IL-5 
and IL-13. In parallel, naïve tTreg activated by an antigen in 
the presence of high IL-4 are activated to express Il5ra. Treg 
activated by the parasite will suppress effector responses 
directed at the parasite. In our experiments, there is a sec-
ond immune response to MBP, which activates Th17, Th1, 
and Th2 responses. Normally, the Th17 and Th1 response 
dominate, and IL-2 induces naïve CD4+CD25+ Treg activated 
by MBP to express Ifngr and Il12rb2. This produces potent 
antigen-specific Treg that control the effector response to 
MBP so clinical disease abates and animals recover from 
paralysis. This response is normally driven by IFN-γ (75). 
However, immunization with MBP/CFA also activates 
some effector Th2 cells that initially produce IL-4 (25, 27) 
and this promotes activation of antigen-activated Treg to 
express Il5ra. In the parasite-infected host, the IL-4 from the 
early type-2 response to parasites would increase the number 
of MBP-specific Treg that express Il5ra and these would be 
further expanded by IL-5 produced by the late type-2 response 
to the parasite. These MBP-activated Treg suppressed the 
response to MBP and reduced the severity of EAE.
The results as a whole are consistent with IL-5 that is produced 
in excess by the type-2 response to the parasites, promoting 
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earlier expansion of autoantigen-specific Treg that limit the 
severity of immune injury in EAE. The identification of IL-5 as a 
key molecule in reducing immunity to autoantigens, some infec-
tions, vaccines, and exacerbating responses to allergens, makes 
IL-5 a target to block and restore protective or less destructive 
immunity.
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